Key highlights
- FDA 510(k) clearance granted for the Tandem Mobi tubeless cartridge and infusion set
- System supports up to 7 days of wear for the infusion set and 3 days for the cartridge
- Full commercial launch scheduled for the first half of 2027 in the United States
- Integrated with Control-IQ technology for advanced hybrid closed-loop insulin delivery
- Tandem Mobi becomes the only pump on the market offering users a choice between wear styles
What Approval Was Received?
Tandem Diabetes Care received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new tubeless cartridge and infusion set for its Tandem Mobi system. This clearance transforms the existing Mobi platform into the first automated insulin delivery (AID) system capable of functioning as both a traditional tubed pump and a tubeless wearable. The newly approved infusion set is cleared for up to seven days of wear, while the associated cartridge is cleared for three days of use. This flexibility allows patients to switch between wear styles depending on their daily needs or activity levels.
Up 5.5% since our story on 13 Nov: $17.51 when we broke it → $18.48 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $16.38 |
|---|---|
| 20 Oct | $16.52 |
| 21 Oct | $16.35 |
| 22 Oct | $17.15 |
| 23 Oct | $17.43 |
| 26 Oct | $18.90 |
| 27 Oct | $19.22 |
| 28 Oct | $19.68 |
| 29 Oct | $19.79 |
| 30 Oct | $19.11 |
| 2 Nov | $18.67 |
| 3 Nov | $17.65 |
| 4 Nov | $19.05 |
| 5 Nov | $17.99 |
| 6 Nov | $16.91 |
| 9 Nov | $18.17 |
| 10 Nov | $18.71 |
| 11 Nov | $18.77 |
| 12 Nov | $17.51 |
| 13 Nov | $20.07 |
| 16 Nov | $18.48 |
Why This Approval Matters
- Eliminates the requirement for permanent tubing, addressing a major preference for users seeking discreet insulin delivery.
- Introduces the only dual-modality pump in the diabetes tech market, providing a competitive alternative to single-use patch pumps.
- Leverages established Control-IQ hybrid closed-loop technology to automate insulin delivery based on glucose levels.
- Extends the infusion set wear time to seven days, reducing the frequency of site changes for patients.
Path to Market
Following the FDA clearance, Tandem Diabetes Care plans a phased approach toward commercial availability. A full commercial launch of the tubeless cartridge and infusion set is slated for the first half of 2027 within the United States. This timeline allows the company to scale its manufacturing and supply chain operations for the new components. The Mobi pump itself is already a flagship in Tandem portfolio, and this update expands its addressable market by targeting the significant segment of insulin users who prefer tubeless patch style devices over traditional hardware.
Business Overview
Headquartered in San Diego, Tandem Diabetes Care is a medical device manufacturer focused on insulin delivery for people with type 1 diabetes. The company reported annual revenue of approximately $1.01 billion, supported by its t:slim X2 pump and the more recent Mobi platform. By integrating with continuous glucose monitors like the Dexcom G6 and G7, Tandem has established a strong presence in the automated insulin delivery sector. The addition of a tubeless option places the company in direct competition with specialized patch-pump manufacturers while maintaining its legacy tubed-pump market share.
| Share price | $17.51 |
|---|---|
| Market cap | $1.2B |
| Revenue (annual) | $1.0B |
| 1-month price change | +5.17% |
| Sector | HealthcareMedical Devices |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Tandem Diabetes Care, Inc. announcing FDA 510(k) clearance for Tandem Mobi.
Track TANDEM DIABETES CARE INC live
Get the next TANDEM DIABETES CARE INC SEC filing seconds after it lands.



